Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study
Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), C. Atchison(Amgen (United States)), Ira Jacobs(Pfizer (United States)), Keith M. Skubitz(Palmetto Hematology Oncology), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Paul Glare(Memorial Sloan Kettering Cancer Center), Karen Chung(Amgen (United States)), Martin Dominkus(Vienna General Hospital), Arthur P. Staddon(University of Pennsylvania), Yi Qian(Amgen (United States)), Ronald H. Blum(St. Luke's-Roosevelt Hospital Center), Amy Feng(Amgen (United States)), Kristin N. Ganjoo(Stanford University), Ada Braun(Amgen (United States)), Jacob Engellau
Cited by 69
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k